Investors Overview
Overview
Alvotech is a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
05
Jul '22
22
Jun '22
22
Jun '22
15
Jun '22
Recent Events
June 23, 2022
June 16, 2022
December 7, 2021
Featured Reports
More information is coming soon.